Italy · research
Italy · researchSibylla Biotech
Sibylla Biotech developed small molecule folding interfering degraders (FIDs) that can address a range of therapeutic areas.
PrivateFor profit
Against its peers
Set against 32 research companies in Italy. The ring marks the typical peer.
Across all 5.9M companies: larger than 33% of those with a size listed; older than 5% of those with a founding year; website ranked #10,801,876 in the world, about 199 visits a month.
About Sibylla Biotech
BiotechnologyHealth CareMedicalPharmaceutical
Funding, as listed
What the source datasets report. We have not watched these rounds ourselves.
$23M
raised in total, currency not stated across 1 round
Last raised Oct 2022, 4 years ago
- Rounds
- 1
- Latest round
- Series a
- Investors
- 81 leading
Every detail we hold
Everything the source datasets list about Sibylla Biotech, field by field. Contact details are held but never shown.
The company6 fields
- Name
- Sibylla Biotech
- Type
- For profit
- Status
- Private
- Founded
- 2017
- Industry
- research
- Categories
- Biotechnology, Health Care, Medical, Pharmaceutical
Where3 fields
- City
- Bresso
- Country
- Italy
- Markets
- European Union (EU), Europe, Middle East, and Africa (EMEA)
Size and reach3 fields
- Staff band
- 11-50
- Web traffic rank
- #10,801,876
- Monthly web visits
- 199
Show 9 more fieldsShow fewer fields
Funding, as listed7 fields
- Total
- 23,000,000 (currency not stated)
- Rounds
- 1
- Latest round
- Series a
- Latest round date
- Oct 2022
- Investors
- 8
- Lead investors
- 1
- Listing status
- private
About this record2 fields
- Sources
- Crunchbase
- Last imported
- Sept 2026
Growth, as the source summarises it
Sibylla Biotech may be growing as evidenced by its strategic collaboration with MD Anderson to discover and develop small-molecule protein degraders, which is a significant partnership in the biotechnology and pharmaceutical industry. The collaboration is focused on joint discovery efforts, indicating an expansion of research and development capabilities. Additionally, the company has garnered attention for its technology that is considered a 'paradigm shift in drug design,' suggesting a positive reception in the market and potential for increased investment or adoption of their technology.
Companies like Sibylla Biotech
research in Italy.
GenespireMilan · 1-10 peoplefounded 3 years later
Resalis TherapeuticsTurin · 1-10 peoplefounded 4 years later
Altheia ScienceMilan · 1-10 peoplefounded the same year
ALKemist BioTurin · 1-10 peoplefounded 6 years later
CanaxMilan · 1-10 peoplefounded 2 years later
Repron TherapeuticsMilan · 1-10 peoplefounded 6 years laterBuild a lead list
32 research companies in Italy, filtered by size, age and reach, ready to export with emails on Pro.